跳至主要内容
临床试验/NCT03167684
NCT03167684Unknown不适用

The Effect of Oral Appliance Therapy on Cardiometabolic Outcomes in Patients With Type 2 Diabetes and Obstructive Sleep Apnea: A Pilot RCT

McGill University Health Centre/Research Institute of the McGill University Health Centre1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
1
主要终点
Recruitment and retention rates

研究概览

简要总结

This study will evaluate the impact on blood glucose of the use of an oral appliance to treat obstructive sleep apnea (OSA) in individuals with Type 2 diabetes. An oral appliance is similar to a sports mouth guard or an orthodontic retainer and is an alternative treatment to continuous positive airway pressure (CPAP) for OSA. Oral appliance therapy has not been evaluated in patients with Type 2 diabetes with respect to glycemic outcomes. This will be a 1:1 randomized controlled trial: The experimental group will receive the oral appliance and the control group will receive a sham device over the course of approximately 5 months.

详细描述

OSA is quite common in individuals with T2DM, occurring in as many as 60-80% of patients. The standard treatment for OSA is with the use of a CPAP machine. The CPAP provides an air pressure to keep the airways opened during sleep so that a person with OSA can breathe normally. When used appropriately, the CPAP improves sleepiness and quality of life. However, about half of the patients who receive a CPAP prescription cannot tolerate it and thus remain untreated and are potentially at increased cardiovascular and diabetes risk. In light of this, this study aims to see if the use of an alternative treatment for OSA, oral appliance therapy, where adherence is generally superior to CPAP, will improve cardiometabolic outcomes in individuals with Type 2 diabetes. This pilot trial will primarily examine feasibility and assess recruitment rates.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of T2DM using current Canadian guidelines
  • •OSA with AHI > 10 events/hour using current American Academy of Sleep Medicine (AASM) criteria for scoring respiratory events

排除标准

  • •On treatment for OSA within the past 3 months
  • •Professional drivers or patients with an increased risk of driving-related accidents from clinical interview or severe subjective sleepiness (Epworth sleepiness scale greater than 15)
  • •Sleep apnea with any of the following features: highly severe OSA (AHI>50 and oxygen desaturation index > 50), severe hypoxemia (SpO2<80% for >10% of recording time), central sleep apnea or Cheyne-Stokes respirations with a central apnea index >10 events/hour
  • •Coexisting sleep disorder other than OSA
  • •Active cardiovascular disease, including angina, arrhythmia or congestive heart failure
  • •Insufficient dentition or significant periodontal disease or other contraindication for OAT as determined by dentist qualified in OSA treatment
  • •Active and significant psychiatric disease
  • •Regular use of sedatives or narcotics

研究组 & 干预措施

Oral appliance therapy

Experimental

Oral appliance (SomnoMed) worn nightly

干预措施: Oral appliance therapy (Device)

Control

No Intervention

Sham oral appliance device

结局指标

主要结局

Recruitment and retention rates

时间窗: End of study (Week 20)

feasibility of study in T2DM

Glycemic control (mean 24-hour and nocturnal glucose)

时间窗: End of study (week 20)

24-hour continuous glucose monitoring

次要结局

  • Blood pressure(End of study (Week 20))
  • Glucose variability(End of study (Week 20))
  • Changes in insulin or diabetes medication doses(End of study (Week 20))
  • Systemic inflammation(End of study (Week 20))

研究者

发起方
McGill University Health Centre/Research Institute of the McGill University Health Centre
申办方类型
Other
责任方
Principal Investigator
主要研究者

Sushmita Pamidi

Clinician Investigator

McGill University Health Centre/Research Institute of the McGill University Health Centre

研究点 (1)

Loading locations...

相似试验